Group 1 - Cathay Pacific Airways (00293) experienced a decline of over 3%, with a significant drop of more than 9% the previous day, currently trading at HKD 10.49 with a transaction volume of HKD 162 million [1] - The company reported a mid-year performance for 2025, with total revenue of HKD 54.309 billion, representing a year-on-year increase of 9.5%, and a net profit attributable to shareholders of HKD 3.651 billion, up 1.1% [1] - The interim dividend declared is HKD 0.20 per share [1] Group 2 - Cathay Pacific announced the exercise of a purchase option under a 2013 subscription agreement to acquire 14 Boeing 777-9 aircraft, with a basic price of approximately USD 8.1 billion, equivalent to about HKD 63.2 billion, expecting a lower actual cost due to significant discounts from the manufacturer [1] - Morgan Stanley's report indicated that the net profit attributable to ordinary shareholders for the first half of the year increased by 8.3% year-on-year, while operating profit remained flat at HKD 5.9 billion, below market expectations of HKD 6.6 billion [1] - The passenger yield was below expectations, primarily due to the normalization of long-haul route yields and increased competition on short-haul routes, despite strong demand in business class and an increase in passenger load factor year-on-year [1] Group 3 - The market generally anticipates a year-on-year decline in net profit for the full year of 2025, but Morgan Stanley believes the downside risk is limited [1] - The rating is "in line with the market," with a target price set at HKD 12.1 [1]

Major Events - Cathay Pacific (00293) has purchased fourteen Boeing 777-9 aircraft [1] - Hengrui Medicine (01276) received FDA orphan drug designation for the combination of injection Rituximab and chemotherapy for gastric cancer or gastroesophageal junction adenocarcinoma [1] - China National Pharmaceutical Group's self-developed drug TQ05105 (JAK/ROCK inhibitor) has been included in the breakthrough therapy designation program [1] - Junshi Biosciences (02696) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanli Kang® for active glomerulonephritis in China [1] - YingTai Medical (01501) plans to invest no more than 110 million yuan to establish the Huai Ge Guang Tai Fund [1] - JinJing New Energy (01783) proposed a stock split [1] Financial Data - Cathay Pacific (00293) reported a mid-term profit attributable to shareholders of 3.651 billion HKD, a year-on-year increase of 1.1%, with an interim dividend of 0.20 HKD per share [1] - Uni-President Enterprises China (00220) reported a mid-term profit attributable to shareholders of 1.287 billion CNY, a year-on-year increase of 33.24% [1] - BeiGene (06160) reported a net profit of 94.32 million USD for the second quarter, returning to profitability year-on-year [1] - Sun Hung Kai Properties (00086) issued a profit warning, expecting mid-term profit attributable to shareholders to increase to no less than 800 million HKD year-on-year [1] - Weixin Jinke (02003) issued a profit warning, expecting mid-term comprehensive net profit to be no less than 200 million CNY, a significant year-on-year increase [1] - ZhiZi Cheng Technology (09911) issued a profit warning, expecting mid-term profit attributable to shareholders to increase by approximately 108.9% to 126.7% year-on-year [1] - China Star Optoelectronics (00334) issued a profit warning, expecting a year-on-year increase of no less than 600% in profit attributable to the parent company for the first half of the year [1] - Xinli International (00732) reported a total operating revenue of approximately 1.468 billion HKD in July, a year-on-year decrease of about 3.3% [1]

Major Events - Cathay Pacific (00293) has purchased fourteen Boeing 777-9 aircraft [1] - Hengrui Medicine (01276) received FDA orphan drug designation for the combination of injection Rituximab and chemotherapy for gastric cancer or gastroesophageal junction adenocarcinoma [1] - China National Pharmaceutical Group (01177) has its self-developed drug TQ05105 (JAK/ROCK inhibitor) included in the breakthrough therapy designation program [1] - Junshi Biosciences (02696) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanli Kang® for active glomerulonephritis in China [1] - YingTai Medical (01501) plans to invest no more than 110 million yuan to establish the Huai Ge Guang Tai Fund [1] - JinJing New Energy (01783) proposed a stock split [1] Financial Data - Cathay Pacific (00293) reported a mid-term profit attributable to shareholders of 3.651 billion HKD, a year-on-year increase of 1.1%, with an interim dividend of 0.2 HKD per share [1] - Uni-President Enterprises China (00220) reported a mid-term profit attributable to shareholders of 1.287 billion CNY, a year-on-year increase of 33.24% [1] - BeiGene (06160) reported a net profit of 94.32 million USD in the second quarter, returning to profitability year-on-year [1] - New World Development Company (00086) issued a profit warning, expecting mid-term profit attributable to shareholders to increase to no less than 800 million HKD year-on-year [1] - Weixin Jinkao (02003) issued a profit warning, expecting mid-term comprehensive net profit to be no less than 200 million CNY, a significant year-on-year increase [1] - ZhiZi Cheng Technology (09911) issued a profit warning, expecting mid-term profit attributable to shareholders to increase by approximately 108.9% to 126.7% year-on-year [1] - Huaxian Optoelectronics (00334) issued a profit warning, expecting a year-on-year increase of no less than 600% in profit attributable to the parent company [1] - Xinli International (00732) reported a total operating revenue of approximately 1.468 billion HKD in July, a year-on-year decrease of about 3.3% [1]

Core Viewpoint - Cathay Pacific reported a net profit of HKD 36.51 billion for the first half of the year, a year-on-year increase of 1.1%, with revenue reaching HKD 543.09 billion, up 9.5% [2][3] Financial Performance - The growth in performance is attributed to increased passenger volume, stable cargo performance, and a 13% decrease in fuel costs due to lower fuel prices [3] - Passenger capacity increased by 26.3% year-on-year, with passenger turnover rising by 30% and average daily passenger count up by 27.8%, resulting in a seat load factor of 84.8%, an increase of 2.4 percentage points [3] - Despite the strong demand for passenger transport, overall yield declined by 12.3% due to increased market capacity [3] Fleet Expansion - Cathay Pacific announced the exercise of a purchase option to acquire 14 Boeing 777-9 aircraft, with the first delivery expected in 2027 [4] Cargo Operations - Cargo revenue increased by 2.2% year-on-year, with cargo capacity up by 8.1% and cargo volume rising by 11.4%, although yield decreased by 3.4% [5] - The cargo sector faces challenges due to geopolitical factors and changes in customs policies, particularly affecting cross-border logistics [5] - The company is focusing on exploring cargo demand in other regions, such as Southeast Asia and India, while also investing in diverse cargo services [5] Strategic Focus - Cathay Pacific is expanding its presence in the Greater Bay Area, enhancing connectivity and services to attract travelers from this region [6] - The company plans to continue expanding domestic routes and has established IT offices in Guangzhou and Shenzhen, with a target of increasing mainland staff to 4,000 by the end of the year [6]

Core Viewpoint - Cathay Pacific Airways announced its mid-year results for 2025 and revealed plans to purchase an additional 14 Boeing 777-9 aircraft, increasing its total order to 35 units [1][3]. Group 1: Financial Details - The basic price for the 14 additional aircraft is approximately $8.1 billion (around HKD 63.2 billion), but the actual cost will be lower due to significant discounts from the manufacturer [3]. - The company’s current market capitalization is HKD 69.868 billion, with a share price of HKD 10.85 [1]. Group 2: Strategic Partnerships - Cathay Pacific has a long-standing partnership with both Airbus and Boeing, with each manufacturer’s aircraft making up about half of its fleet [3]. - The management emphasized the importance of maintaining long-term relationships with both manufacturers [3]. Group 3: Aircraft Performance and Future Plans - The chairman of Cathay Pacific expressed confidence in Boeing's commitment to improving production quality and engineering, noting that Boeing has resumed test flights with four aircraft having completed over 1,400 flights totaling more than 4,000 hours [3]. - The company plans to integrate the new Boeing 777-9 aircraft into its fleet by 2027 and remains open to acquiring more in the future [3].

Major Events - Cathay Pacific (00293) has purchased fourteen Boeing 777-9 aircraft [1] - Hengrui Medicine (01276) received FDA orphan drug designation for injection of Rukang Qutuzumab combined with Atezolizumab and chemotherapy for gastric cancer or gastroesophageal junction adenocarcinoma [1] - China National Pharmaceutical Group (01177) has its self-developed TQ05105 (JAK/ROCK inhibitor) included in the breakthrough therapy designation program [1] - Junshi Biosciences (02696) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanlikang® for active glomerulonephritis in China [1] - YingTai Medical (01501) plans to invest no more than 110 million yuan to establish the Huai Ge Guang Tai Fund [1] - JinJing New Energy (01783) proposed a stock split [1] Financial Data - Cathay Pacific (00293) reported a mid-term profit attributable to shareholders of 3.651 billion HKD, a year-on-year increase of 1.1%, with an interim dividend of 0.20 HKD per share [1] - Uni-President Enterprises China (00220) reported a mid-term profit attributable to shareholders of 1.287 billion CNY, a year-on-year increase of 33.24% [1] - BeiGene (06160) reported a net profit of 94.32 million USD for the second quarter, returning to profitability year-on-year [1] - Sun Hung Kai Properties (00086) issued a profit warning, expecting mid-term profit attributable to shareholders to increase to no less than 800 million HKD year-on-year [1] - Weimeng Jin Ke (02003) issued a profit warning, expecting mid-term comprehensive net profit to be no less than 200 million CNY, a significant year-on-year increase [1] - Zhi Zi Cheng Technology (09911) issued a profit warning, expecting mid-term profit attributable to shareholders to increase by approximately 108.9% to 126.7% year-on-year [1] - China Star Optoelectronics Technology (00334) issued a profit warning, expecting a year-on-year increase of no less than 600% in profit attributable to the parent company for the first half of the year [1] - Xinli International (00732) reported a total operating revenue of approximately 1.468 billion HKD in July, a year-on-year decrease of about 3.3% [1]

Core Viewpoint - Cathay Pacific Airways announced its mid-year results for 2025 and revealed plans to purchase an additional 14 Boeing 777-9 aircraft, increasing its total orders for this model to 35 units [2] Group 1: Financial Details - The basic price for the additional 14 aircraft is approximately $8.1 billion (around HKD 63.2 billion), with the actual cost expected to be lower due to significant discounts from the manufacturer [2] - The company's current market capitalization is HKD 69.868 billion, with a share price of HKD 10.85 [2] Group 2: Strategic Partnerships - Cathay Pacific has a long-standing partnership with both Airbus and Boeing, with each manufacturer’s aircraft making up roughly half of the fleet [2] - The management emphasized the importance of maintaining long-term relationships with both manufacturers [2] Group 3: Confidence in Boeing - The Chairman of Cathay Pacific expressed confidence in Boeing, noting that the company is prioritizing production quality and engineering amidst challenges [2] - Boeing has resumed test flights, with four aircraft currently undergoing testing, totaling over 1,400 flights and 4,000 hours [2] - Cathay Pacific aims to incorporate the new Boeing 777-9 aircraft into its fleet by 2027 and remains open to acquiring more in the future [2]

Group 1: Market Performance - The US stock market showed mixed results with the Dow Jones down by 0.18%, while the Nasdaq rose by 0.18% and the S&P 500 increased by 0.05% [1] - Chinese concept stocks saw significant gains, with companies like Bawang Chaji and Atour Group rising over 3%, while Cathay Pacific experienced a decline of over 10% [1] Group 2: Company News - Tesla's sales in Europe have drastically declined, with sales in Germany dropping by 55.1% in July, totaling only 1,110 vehicles sold, and a year-to-date decline of 57.8% [5] - Apple Inc. announced a commitment to reinvest $100 billion in US manufacturing, leading to a nearly 3% increase in its stock price, reaching $208.81 [6] - Cathay Pacific reported a 9.5% increase in revenue for the first half of the year, totaling HKD 54.309 billion, and plans to purchase an additional 14 Boeing 777-9 aircraft, raising its total order to 35 [7]

Core Viewpoint - Cathay Pacific Airways announced its mid-year results for 2025 and revealed plans to purchase an additional 14 Boeing 777-9 aircraft, increasing its total orders for this model to 35 aircraft [1][2]. Group 1: Financials and Aircraft Orders - The basic price for the additional 14 Boeing 777-9 aircraft is approximately $8.1 billion (around HKD 63.2 billion), with the actual cost expected to be lower due to significant discounts from the manufacturer [1]. - The company maintains a balanced fleet with aircraft from both Boeing and Airbus, each accounting for roughly half of its fleet [1]. Group 2: Management Insights - The Chairman of Cathay Pacific expressed confidence in Boeing's leadership focusing on production quality and engineering, which is crucial for the airline's future operations [2]. - The airline is optimistic about integrating the new Boeing 777-9 aircraft into its fleet by 2027 and plans to remain flexible in future acquisitions of this aircraft model [2].

Group 1: Financial Performance - Cathay Pacific reported a net profit of HKD 36.51 billion for the first half of the year, representing a year-on-year increase of 1.1% [1] - The company's revenue reached HKD 543.09 billion, showing a year-on-year growth of 9.5% [1] - The increase in profit was attributed to higher passenger volumes, stable cargo performance, and a 13% decrease in fuel costs due to lower fuel prices compared to previous years [1] Group 2: Operational Metrics - Passenger capacity increased by 26.3% year-on-year, while passenger turnover rose by 30% [1] - The average daily passenger load increased by 27.8%, with a seat load factor of 84.8%, up by 2.4 percentage points year-on-year [1] - Despite the strong demand for passenger transport, overall yield declined by 12.3% due to increased market capacity [1] Group 3: Future Outlook and Investments - The company plans to maintain strong demand momentum in the second half of the year, despite the impact of increased capacity on ticket prices and yields [1] - Cathay Pacific announced the exercise of a purchase option to acquire 14 additional Boeing 777-9 aircraft, with the first delivery expected in 2027 [2]